Gene
NTRK3
NTRK3 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (2), Assay-provider ledger (38), Actionable biomarkers (5), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention NTRK3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 4 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 1 of 8,275 | 0.01% | 11 of 11,460 | 0.10% |
| 2022 | 0 of 8,285 | 0.00% | 18 of 13,598 | 0.13% |
| 2021 | 3 of 8,692 | 0.03% | 17 of 15,045 | 0.11% |
| 2020 | 1 of 7,640 | 0.01% | 14 of 14,459 | 0.10% |
| 2019 | 1 of 7,300 | 0.01% | 20 of 12,159 | 0.16% |
| 2018 | 1 of 6,927 | 0.01% | 12 of 11,854 | 0.10% |
| 2017 | 4 of 6,558 | 0.06% | 9 of 11,595 | 0.08% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (2)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| FoundationOne CDx | NTRK3 | Foundation Medicine, Inc. | Solid Tumors | 2022-06-07 |
| FoundationOne CDx | NTRK3 | Foundation Medicine, Inc. | Solid Tumors | 2020-10-23 |
Assay-provider ledger (38)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Foundation Medicine | Diagnostic provider | Clinical validationAnalytical validation | 4 | August 01, 2026 +1 undated |
| Olympus Corporation of Americas | Reagent supplier | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 4 | August 01, 2026 |
| University of Pittsburgh Medical Center (UPMC) Molecular & Genomics Pathology (MGP) laboratory | Not a company | Clinical validationAnalytical validation | 1 | August 01, 2026 |
| University of Pittsburgh Medical Center | Not a company | Clinical validationAnalytical validation | 3 | April 01, 2026 |
Showing 5 of 38 assay-provider companies.
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| NTRK3 fusion | Midostaurin | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NTRK3 fusion | Pi3k Pathway Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NTRK3 fusion | Igf1r Inhibitors | response-associated | breast adenocarcinoma | Cancer Genome Interpreter |
| NTRK3 (G623R) | Novel Trk Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
| NTRK3 (G623R) | Larotrectinib | responsive | No disease recorded | Cancer Genome Interpreter |
Trial mentions (25)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04617054 | Trial eligibility (AACT) |
| NCT03215511 | Trial eligibility (AACT) |
| NCT06133374 | Trial eligibility (AACT) |
| NCT07843550 | Trial eligibility (AACT) |
| NCT02473497 | Trial eligibility (AACT) |
Showing 5 of 25 trial mentions.
Target-disease associations (465)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-phosphoinositide-dependent protein kinase 1 measurement | measurement | GWAS credible sets |
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Abnormal sperm morphology | phenotype | Expression Atlas |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 465 associations.
Vendor sourcing (77)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Alberta Health Services | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Age ≥ 18 years * A diagnosis of papillary thyroid cancer based on a fine needle biopsy (FNB) interpreted as a Bethesda V or VI cytology * A diagnosis of... | View trial NCT06133374 |
| Alberta Health Services | Trial collaborator | Mentioned in trial textTrial free-text mention | NTRK3 | View trial NCT06133374 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.1835C>A (p.P612H) alteration is located in exon 16 (coding exon 14) of the NTRK3 gene. This alteration results from a C to A substitution at nucleotide... | View ClinVar record SCV003580524.2 |
| AnHeart Therapeutics Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Diagnosed with locally advanced or metastatic solid tumors harboring NTRK1, NTRK2, or NTRK3 fusion genes (anticipated to translate into fusion proteins... | View trial NCT04617054 |
| AnHeart Therapeutics Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for whi... | View trial NCT02279433 |
Showing 5 of 77 sourcing records.
Trial-cited literature (140)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Molecular Diagnostics and [<sup>18</sup>F]FDG-PET/CT in Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources? | Thyroid : official journal of the American Thyroid Association | 2024 | 11 |
| BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. | NPJ precision oncology | 2024 | 6 |
| A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies. | Cancer discovery | 2023 | 41 |
| The tumor-nerve circuit in breast cancer. | Cancer metastasis reviews | 2023 | 34 |
| Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects. | Biomarker research | 2023 | 26 |
Showing 5 of 140 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.D499N | 1 | 2015 | PMID 25741868 |
| p.G623R | 3 | 2016 to 2018 | PMID 29466156, PMID 29606586, PMID 26884591 |
Literature-extracted relations (27)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Crizotinib | Chemical | negative_correlate |
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. | 2014 |
| Melanoma | Disease | associate |
BPI-28592 as a novel second generation inhibitor for NTRK fusion tumors. | 2024 |
| Neoplasms | Disease | associate |
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. | 2021 |
| Carcinoma, Pancreatic Ductal | Disease | associate |
High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. | 2021 |
| Neoplasms | Disease | associate |
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. | 2020 |
Showing 5 of 27 relation assertions.
Organizations publishing (205)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 13 | 2016 to 2023 |
| Mass General Brigham | Hospital | 10 | 2015 to 2022 |
| The University of Texas System | Academic | 9 | 2016 to 2022 |
| University of California System | Academic | 9 | 2011 to 2022 |
| Novant Health | Hospital | 8 | 2014 to 2022 |
Showing 5 of 205 organizations.
Where NTRK3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- psychiatric disorder
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
425 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.